vs
Medpace Holdings, Inc.（MEDP）与Rackspace Technology, Inc.（RXT）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是Rackspace Technology, Inc.的1.0倍（$708.5M vs $682.8M），Medpace Holdings, Inc.净利率更高（19.1% vs -4.8%，领先23.9%），Medpace Holdings, Inc.同比增速更快（32.0% vs -0.4%），Medpace Holdings, Inc.自由现金流更多（$188.1M vs $56.0M），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs -0.6%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
Rackspace Technology, Inc.是总部位于美国得克萨斯州圣安东尼奥的云计算企业，在弗吉尼亚州雷斯顿以及澳大利亚、加拿大、英国、印度、迪拜、瑞士、荷兰、德国、新加坡、墨西哥、中国香港等多个国家和地区设有办事处，数据中心分布于全球多个主要城市，为客户提供专业的云计算相关服务。
MEDP vs RXT — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $682.8M |
| 净利润 | $135.1M | $-32.7M |
| 毛利率 | — | 17.6% |
| 营业利润率 | 21.6% | -0.5% |
| 净利率 | 19.1% | -4.8% |
| 营收同比 | 32.0% | -0.4% |
| 净利润同比 | 15.5% | 41.6% |
| 每股收益（稀释后） | $4.65 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $708.5M | $682.8M | ||
| Q3 25 | $659.9M | $671.2M | ||
| Q2 25 | $603.3M | $666.3M | ||
| Q1 25 | $558.6M | $665.4M | ||
| Q4 24 | $536.6M | $685.6M | ||
| Q3 24 | $533.3M | $675.8M | ||
| Q2 24 | $528.1M | $684.9M | ||
| Q1 24 | $511.0M | $690.8M |
| Q4 25 | $135.1M | $-32.7M | ||
| Q3 25 | $111.1M | $-67.1M | ||
| Q2 25 | $90.3M | $-54.5M | ||
| Q1 25 | $114.6M | $-71.5M | ||
| Q4 24 | $117.0M | $-56.0M | ||
| Q3 24 | $96.4M | $-186.6M | ||
| Q2 24 | $88.4M | $25.0M | ||
| Q1 24 | $102.6M | $-640.6M |
| Q4 25 | — | 17.6% | ||
| Q3 25 | — | 19.4% | ||
| Q2 25 | — | 19.4% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 19.2% | ||
| Q3 24 | — | 20.3% | ||
| Q2 24 | — | 19.2% | ||
| Q1 24 | — | 19.2% |
| Q4 25 | 21.6% | -0.5% | ||
| Q3 25 | 21.5% | -5.1% | ||
| Q2 25 | 20.9% | -3.8% | ||
| Q1 25 | 20.3% | -5.8% | ||
| Q4 24 | 23.4% | -4.2% | ||
| Q3 24 | 21.1% | -25.7% | ||
| Q2 24 | 19.9% | -7.9% | ||
| Q1 24 | 20.4% | -94.5% |
| Q4 25 | 19.1% | -4.8% | ||
| Q3 25 | 16.8% | -10.0% | ||
| Q2 25 | 15.0% | -8.2% | ||
| Q1 25 | 20.5% | -10.7% | ||
| Q4 24 | 21.8% | -8.2% | ||
| Q3 24 | 18.1% | -27.6% | ||
| Q2 24 | 16.7% | 3.7% | ||
| Q1 24 | 20.1% | -92.7% |
| Q4 25 | $4.65 | $-0.13 | ||
| Q3 25 | $3.86 | $-0.28 | ||
| Q2 25 | $3.10 | $-0.23 | ||
| Q1 25 | $3.67 | $-0.31 | ||
| Q4 24 | $3.67 | $-0.20 | ||
| Q3 24 | $3.01 | $-0.82 | ||
| Q2 24 | $2.75 | $0.11 | ||
| Q1 24 | $3.20 | $-2.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $105.8M |
| 总债务越低越好 | — | $2.7B |
| 股东权益账面价值 | $459.1M | $-1.2B |
| 总资产 | $2.0B | $2.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $497.0M | $105.8M | ||
| Q3 25 | $285.4M | $99.5M | ||
| Q2 25 | $46.3M | $103.9M | ||
| Q1 25 | $441.4M | $128.0M | ||
| Q4 24 | $669.4M | $144.0M | ||
| Q3 24 | $656.9M | $157.1M | ||
| Q2 24 | $510.9M | $190.2M | ||
| Q1 24 | $407.0M | $282.6M |
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | — | $2.8B | ||
| Q2 24 | — | $2.9B | ||
| Q1 24 | — | $3.0B |
| Q4 25 | $459.1M | $-1.2B | ||
| Q3 25 | $293.6M | $-1.2B | ||
| Q2 25 | $172.4M | $-1.1B | ||
| Q1 25 | $593.6M | $-1.1B | ||
| Q4 24 | $825.5M | $-1.0B | ||
| Q3 24 | $881.4M | $-949.7M | ||
| Q2 24 | $763.6M | $-756.2M | ||
| Q1 24 | $671.5M | $-787.2M |
| Q4 25 | $2.0B | $2.8B | ||
| Q3 25 | $1.8B | $2.8B | ||
| Q2 25 | $1.6B | $2.9B | ||
| Q1 25 | $1.9B | $3.0B | ||
| Q4 24 | $2.1B | $3.1B | ||
| Q3 24 | $2.1B | $3.1B | ||
| Q2 24 | $1.9B | $3.4B | ||
| Q1 24 | $1.8B | $3.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $59.7M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | $56.0M |
| 自由现金流率自由现金流/营收 | 26.6% | 8.2% |
| 资本支出强度资本支出/营收 | 0.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $681.9M | $90.6M |
8季度趋势，按日历期对齐
| Q4 25 | $192.7M | $59.7M | ||
| Q3 25 | $246.2M | $70.7M | ||
| Q2 25 | $148.5M | $8.4M | ||
| Q1 25 | $125.8M | $12.6M | ||
| Q4 24 | $190.7M | $54.3M | ||
| Q3 24 | $149.1M | $51.8M | ||
| Q2 24 | $116.4M | $24.1M | ||
| Q1 24 | $152.7M | $-90.3M |
| Q4 25 | $188.1M | $56.0M | ||
| Q3 25 | $235.5M | $42.7M | ||
| Q2 25 | $142.4M | $-12.4M | ||
| Q1 25 | $115.8M | $4.3M | ||
| Q4 24 | $183.0M | $34.4M | ||
| Q3 24 | $138.5M | $27.3M | ||
| Q2 24 | $103.5M | $-14.5M | ||
| Q1 24 | $147.2M | $-118.4M |
| Q4 25 | 26.6% | 8.2% | ||
| Q3 25 | 35.7% | 6.4% | ||
| Q2 25 | 23.6% | -1.9% | ||
| Q1 25 | 20.7% | 0.6% | ||
| Q4 24 | 34.1% | 5.0% | ||
| Q3 24 | 26.0% | 4.0% | ||
| Q2 24 | 19.6% | -2.1% | ||
| Q1 24 | 28.8% | -17.1% |
| Q4 25 | 0.6% | 0.5% | ||
| Q3 25 | 1.6% | 4.2% | ||
| Q2 25 | 1.0% | 3.1% | ||
| Q1 25 | 1.8% | 1.2% | ||
| Q4 24 | 1.4% | 2.9% | ||
| Q3 24 | 2.0% | 3.6% | ||
| Q2 24 | 2.4% | 5.6% | ||
| Q1 24 | 1.1% | 4.1% |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.32× | 0.96× | ||
| Q1 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
RXT
| Public Cloud Services Segment | $442.2M | 65% |
| Private Cloud Service Segment | $240.6M | 35% |
